IL6R and inflammatory bowel disease: However, Tocilizumab has failed in phase II clinical trials for IBD due to non-tolerable side effects (17, 18), including intestinal perforations that were also occasionally observed in patients during anti-IL-6R therapy of rheumatoid arthritis (19).